The development of albendazole for lymphatic filariasis.
Identifieur interne : 005F93 ( Main/Exploration ); précédent : 005F92; suivant : 005F94The development of albendazole for lymphatic filariasis.
Auteurs : J. Horton [Royaume-Uni]Source :
- Annals of tropical medicine and parasitology [ 1364-8594 ] ; 2009.
Descripteurs français
- KwdFr :
- Albendazole (effets indésirables), Albendazole (usage thérapeutique), Animaux, Association de médicaments, Calendrier d'administration des médicaments, Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Santé publique.
- MESH :
- effets indésirables : Albendazole, Filaricides, Ivermectine.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Filaricides, Ivermectine.
- Animaux, Association de médicaments, Calendrier d'administration des médicaments, Filariose lymphatique, Humains, Santé publique.
English descriptors
- KwdEn :
- Albendazole (adverse effects), Albendazole (therapeutic use), Animals, Drug Administration Schedule, Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (prevention & control), Filaricides (adverse effects), Filaricides (therapeutic use), Humans, Ivermectin (adverse effects), Ivermectin (therapeutic use), Public Health.
- MESH :
- chemical , adverse effects : Albendazole, Filaricides, Ivermectin.
- chemical , therapeutic use : Albendazole, Filaricides, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Animals, Drug Administration Schedule, Drug Therapy, Combination, Humans, Public Health.
Abstract
The history of the development of ivermectin and diethylcarbamazine for the treatment of human filarial infections is relatively well known and documented. The story of how albendazole became involved in the global elimination programmes is, however, less well known. This review examines the thinking and the processes behind the development of albendazole, from the first ideas in the mid 1980s to the establishment of the Global Programme to Eliminate Lymphatic Filariasis. Throughout, the approaches were essentially different from those of traditional drug development and, in the end, there was a recommendation for a particular public-health use that was not formally approved by the regulatory authorities. While there is no doubt about the efficacy of albendazole for the treatment of many helminth diseases, as a single agent it could never be recommended for filariasis.
DOI: 10.1179/000349809X12502035776595
PubMed: 19843396
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002C86
- to stream PubMed, to step Curation: 002C86
- to stream PubMed, to step Checkpoint: 002C86
- to stream Ncbi, to step Merge: 003687
- to stream Ncbi, to step Curation: 003687
- to stream Ncbi, to step Checkpoint: 003687
- to stream Main, to step Merge: 006064
- to stream Main, to step Curation: 005F93
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The development of albendazole for lymphatic filariasis.</title><author><name sortKey="Horton, J" sort="Horton, J" uniqKey="Horton J" first="J" last="Horton">J. Horton</name><affiliation wicri:level="1"><nlm:affiliation>Tropical Projects, 24 The Paddock, Hitchin SG4 9EF, UK. hedgepigs@aol.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Tropical Projects, 24 The Paddock, Hitchin SG4 9EF</wicri:regionArea><wicri:noRegion>Hitchin SG4 9EF</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19843396</idno><idno type="pmid">19843396</idno><idno type="doi">10.1179/000349809X12502035776595</idno><idno type="wicri:Area/PubMed/Corpus">002C86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C86</idno><idno type="wicri:Area/PubMed/Curation">002C86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C86</idno><idno type="wicri:Area/PubMed/Checkpoint">002C86</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C86</idno><idno type="wicri:Area/Ncbi/Merge">003687</idno><idno type="wicri:Area/Ncbi/Curation">003687</idno><idno type="wicri:Area/Ncbi/Checkpoint">003687</idno><idno type="wicri:Area/Main/Merge">006064</idno><idno type="wicri:Area/Main/Curation">005F93</idno><idno type="wicri:Area/Main/Exploration">005F93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The development of albendazole for lymphatic filariasis.</title><author><name sortKey="Horton, J" sort="Horton, J" uniqKey="Horton J" first="J" last="Horton">J. Horton</name><affiliation wicri:level="1"><nlm:affiliation>Tropical Projects, 24 The Paddock, Hitchin SG4 9EF, UK. hedgepigs@aol.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Tropical Projects, 24 The Paddock, Hitchin SG4 9EF</wicri:regionArea><wicri:noRegion>Hitchin SG4 9EF</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of tropical medicine and parasitology</title><idno type="eISSN">1364-8594</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (therapeutic use)</term><term>Public Health</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Santé publique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Public Health</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Filariose lymphatique</term><term>Humains</term><term>Santé publique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The history of the development of ivermectin and diethylcarbamazine for the treatment of human filarial infections is relatively well known and documented. The story of how albendazole became involved in the global elimination programmes is, however, less well known. This review examines the thinking and the processes behind the development of albendazole, from the first ideas in the mid 1980s to the establishment of the Global Programme to Eliminate Lymphatic Filariasis. Throughout, the approaches were essentially different from those of traditional drug development and, in the end, there was a recommendation for a particular public-health use that was not formally approved by the regulatory authorities. While there is no doubt about the efficacy of albendazole for the treatment of many helminth diseases, as a single agent it could never be recommended for filariasis.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Horton, J" sort="Horton, J" uniqKey="Horton J" first="J" last="Horton">J. Horton</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005F93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005F93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19843396
|texte= The development of albendazole for lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19843396" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |